Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that injects tumors with radioactive material in simple needle procedure

The 2020 figure represents a 55% year-on-year surge in funding in digital health, medical devices, biotech and pharma firms, IATI says; M&A deals plunge

Startup's blood test aims to predict which cancer patients will react better to treatment; 8 clinical trials will be set up in the UK

Funding will help advance the clinical development of firm's flagship drug for the treatment of solid and blood cancers via multiple clinical trials

Texas's Cancer Focus Fund will support a Phase 1/2 clinical study assessing Israeli company's flagship drug, which uses 2 proteins - 1 to mark cancer cells and 1 to weaken them

In pivot, biotech firm that makes burn and wound treatments will start clinical trial for new drug candidate in Q2 in three US medical centers

Unit of Swiss multinational firm strikes multiyear strategic collaboration with Israeli life-sciences firm that cultures, ferments and delivers bacterial communities for healthcare

Gamida Cell shares surge after results of key trial show flagship drug results in faster blood count recovery, fewer bacterial and viral infections after bone marrow transplants

Hugo Hagen, Bayer's local chief, says the company has invested heavily in Israeli firms and is looking for more: The Israeli 'culture of innovation is amazing'

Biond Biologics hopes its therapy, which activates 3 separate immune pathways, will prove to be 'strong and sustained anti-tumor response,' says CEO; human trials to start mid-2021